Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00503841 · ClinicalTrials.gov registry record · NA
Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer
A NA study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Terminated
- Registry status
- NA
- Development phase
- 44
- Enrollment target
NCT00503841: Clinical Trial NA study, sponsored by Barbara Ann Karmanos Cancer Institute.
NCT00503841 is a NA study that was terminated before completion, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 44 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00503841, a NA study, was terminated before completion, sponsored by Barbara Ann Karmanos Cancer Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
Study Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying how well erlotinib works in treating women undergoing surgery for stage I, stage II, or stage III breast cancer.
Interventions
- OTHER laboratory biomarker analysis
- PROCEDURE biopsy
- OTHER immunohistochemistry staining method
- PROCEDURE conventional surgery
- DRUG erlotinib hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-05 |
| Phase | NA |
Why NCT00503841 stopped before completion
NCT00503841 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00503841 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00503841 about?
NCT00503841 is a clinical study titled "Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer". RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying how well erlotinib works in treating women undergoing surgery for stage I, stage II, or stage III breast cancer.
What is the current status of trial NCT00503841?
This trial is currently terminated. It is a NA study. The enrollment target is 44 participants. The study started on 2007-12. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00503841?
The interventions under investigation include: laboratory biomarker analysis (OTHER), biopsy (PROCEDURE), immunohistochemistry staining method (OTHER), conventional surgery (PROCEDURE), erlotinib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00503841?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00503841's enrollment target sits among peer trials
44 1423rd of 2000 higher than 566 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia